Referencia número: HY-N6961

Lapachol

3 Cited Publications

Revisión del cliente

Based on 3 publication(s) in Google Scholar

Lapachol, a natural naphthoquinone, is an orally active, potent DHODH inhibitor. Lapachol has immunosuppressive activity on lymphocytes through its direct ability to block DHODH activity and inhibit pyrimidine synthesis. Lapachol is a vitamin K antagonist with antitumor activity and can inhibit DNA and RNA synthesis in neoplastic cells. Lapachol has anti-Leishmania activity.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.49%
No. CAS: 84-79-7
Fòrmula: C₁₅H₁₄O₃
Peso molecular:242.27

Almacenamiento:

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Lapachol Chemical Structure

No. CAS: 84-79-7

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

Plasmodium

Leishmania

Ver todos los productos específicos de isoformas DNA/RNA Synthesis :

Ver todos los productos específicos de isoformas Parasite :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	1.9 μM Compound: 3	Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A2780 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
A549	EC₅₀	4.78 μM Compound: 3	Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human A549 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
A549	IC₅₀	8 μM Compound: 1, Lapachol	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 24374273]
A549	IC₅₀	>30 μM Compound: 3	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay	[PMID: 32044231]
A549	CC₅₀	≥285 μM Compound: 28	Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay Cytotoxicity against human A549 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
C6	IC₅₀	3.7 μM Compound: Lapachol	Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS/PMS assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell growth incubated for 48 hrs by MTS/PMS assay	[PMID: 38458106]
DU-145	IC₅₀	64.59 nM Compound: 1	Anticancer activity against human DU145 cells after 72 hrs by XTT assay Anticancer activity against human DU145 cells after 72 hrs by XTT assay	[PMID: 18829316]
ECa-109 cell line	IC₅₀	12.56 μM Compound: Lapachol	Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human ECA109 cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 27667553]
HaCaT	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human HaCaT cells Antiproliferative activity against human HaCaT cells	[PMID: 10479319]
HBL-100	GI₅₀	7.8 μM Compound: 3	Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HBL100 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HBL-100	GI₅₀	7.8 μM Compound: 1	Growth inhibition of human HBL100 cells by SRB assay Growth inhibition of human HBL100 cells by SRB assay	[PMID: 22560628]
HeLa	GI₅₀	2.3 μM Compound: 3	Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay Growth inhibition of human HeLa cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
HeLa	GI₅₀	2.3 μM Compound: 1	Growth inhibition of human HeLa cells by SRB assay Growth inhibition of human HeLa cells by SRB assay	[PMID: 22560628]
HeLa	IC₅₀	20.36 μM Compound: Lapachol	Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell proliferation after 48 hrs by MTT assay	[PMID: 27667553]
HepG2	CC₅₀	>4130.7 μM Compound: 1	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29324340]
HepG2	CC₅₀	≥285 μM Compound: 28	Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
HL-60	IC₅₀	3.18 μM Compound: 1	Cytotoxicity against human promyelocytic leukemia HL60 cell line by MTT assay Cytotoxicity against human promyelocytic leukemia HL60 cell line by MTT assay	[PMID: 17249647]
Hs 683	IC₅₀	11 μM Compound: 1, Lapachol	Growth inhibition of human Hs683 cells by MTT assay Growth inhibition of human Hs683 cells by MTT assay	[PMID: 24374273]
HT-29	EC₅₀	2.84 μM Compound: Lapachol	Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay	[PMID: 24900447]
HT-29	IC₅₀	4.66 μM Compound: Lapachol	Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins	[PMID: 24900447]
K562	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 30003778]
KB	ED₅₀	4.4 μg/mL Compound: 21 (lapachol)	Evaluated for cytotoxicity in the KB cell culture assay Evaluated for cytotoxicity in the KB cell culture assay	[PMID: 3669007]
KB	ED₅₀	4.4 μg/mL Compound: 9	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 7153777]
LLC-PK1	CC₅₀	≥285 μM Compound: 28	Cytotoxicity against human LLC-PK1 cells incubated for 24 hrs by MTT assay Cytotoxicity against human LLC-PK1 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
LoVo	IC₅₀	9 μM Compound: 1, Lapachol	Growth inhibition of human LoVo cells by MTT assay Growth inhibition of human LoVo cells by MTT assay	[PMID: 24374273]
MCF7	EC₅₀	10.15 μM Compound: 3	Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
MCF7	IC₅₀	>30 μM Compound: 3	Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay	[PMID: 32044231]
MDA-MB-231	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 30003778]
MDA-MB-231	IC₅₀	>30 μM Compound: 3	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell proliferation measured after 72 hrs by WST8 assay	[PMID: 32044231]
MRC5	CC₅₀	≥285 μM Compound: 28	Cytotoxicity against human MRC5 cells incubated for 24 hrs by MTT assay Cytotoxicity against human MRC5 cells incubated for 24 hrs by MTT assay	[PMID: 33333397]
P388	IC₅₀	0.2 μg/mL Compound: 2	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 1791483]
PBMC	IC₅₀	2.1 μM Compound: 1, Lapachol	Cytotoxicity against human PBMC after 72 hrs by alamar blue assay Cytotoxicity against human PBMC after 72 hrs by alamar blue assay	[PMID: 20378360]
PBMC	IC₅₀	>103.19 μM Compound: 1	Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay Cytotoxicity against human PBMC after 72 hrs by Alamar blue assay	[PMID: 21820768]
PC-3	EC₅₀	1.97 μM Compound: 3	Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay Antiproliferative activity against human PC3 cells after 72 hrs by trypan blue exclusion assay	[PMID: 19674905]
PC-3	IC₅₀	4 μM Compound: 1, Lapachol	Growth inhibition of human PC3 cells by MTT assay Growth inhibition of human PC3 cells by MTT assay	[PMID: 24374273]
Peritoneal macrophage	CC₅₀	59.3 μM Compound: 10, Lapachol	Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay Cytotoxicity against Swiss mouse peritoneal macrophages after 24 hrs by MTT assay	[PMID: 23535320]
Raji	IC₅₀	311.4 μM Compound: Lapachol	Inhibition of TPA-induced EBV-EA activation in Raji cells Inhibition of TPA-induced EBV-EA activation in Raji cells	[PMID: 17950604]
Raji	IC₅₀	311.4 μM Compound: 3	Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced EBV-early antigen activation in human Raji cells after 48 hrs by immunofluorescence technique	[PMID: 19674905]
SK-MEL-28	IC₅₀	8 μM Compound: 1, Lapachol	Growth inhibition of human SK-MEL-28 cells by MTT assay Growth inhibition of human SK-MEL-28 cells by MTT assay	[PMID: 24374273]
SW1573	GI₅₀	34 μM Compound: 3	Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human SW1573 cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
SW1573	GI₅₀	34 μM Compound: 1	Growth inhibition of human SW1573 cells by SRB assay Growth inhibition of human SW1573 cells by SRB assay	[PMID: 22560628]
T47D	GI₅₀	76 μM Compound: 3	Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay Growth inhibition of human T47D cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
U2OS	EC₅₀	47.9 μM Compound: Lapachol	Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay	[PMID: 24900447]
U-373MG ATCC	IC₅₀	8 μM Compound: 1, Lapachol	Growth inhibition of human U373 cells by MTT assay Growth inhibition of human U373 cells by MTT assay	[PMID: 24374273]
WiDr	GI₅₀	36 μM Compound: 3	Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay Growth inhibition of human WiDr cells after 48 hrs by sulforhodamine B assay	[PMID: 20304655]
WiDr	GI₅₀	36 μM Compound: 1	Growth inhibition of human WiDr cells by SRB assay Growth inhibition of human WiDr cells by SRB assay	[PMID: 22560628]

In Vitro

Lapachol (10, 30, 100 μM; 4 days) inhibits lymphocyte proliferation through inhibition of pyrimidine biosynthesis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:

Murine CD4 T cells
Concentration:

10, 30, 100 μM
Incubation Time:

4 days
Result:

Inhibited the proliferation of murine CD4 T cells in a dose-dependent manner.

In Vivo

Lapachol (3 mg/kg and 10 mg/kg; orally; once a day for 4 weeks) reduces the severity of experimental arthritis in CIA mice models^[1].
Lapachol (10 mg/kg; orally; once a day over 9 days) exhibits a remarkable reduction in leucocyte infiltration into the knee joint 6 h after mBSA challenge in male C57BL/6 mice (6 weeks old) with antigen-induced arthritis (AIA)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male DBA1/J mice (10-12 weeks old) with collagen-induced arthritis (CIA) models^[1]
Dosage:

3 mg/kg and 10 mg/kg
Administration:

Orally; once a day for 4 weeks
Result:

Markedly attenuated the severity of arthritis in CIA mice at both doses.
Markedly reduced all histopathological features of arthritis severity.

Chemical Information

No. CAS 84-79-7
Appearance Solid
Peso molecular 242.27
Fòrmula C₁₅H₁₄O₃
Color Light yellow to yellow
SMILES

O=C(C(CC=C(C)C)=C1O)C2=CC=CC=C2C1=O
Structure Classification
- Quinones
- Naphthalene Quinones
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Publications (3)

All

Sort by:

Journal Impact Factor

PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Solvente y solubilidad

In Vitro:

DMSO : 50 mg/mL (206.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.1276 mL

20.6381 mL

41.2763 mL

5 mM

0.8255 mL

4.1276 mL

8.2553 mL

10 mM

0.4128 mL

2.0638 mL

4.1276 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (276 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Raphael S Peres, et al. Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis. Arthritis Res Ther. 2017 Mar 7;19(1):47. [Content Brief]

[2]. Masayo Maeda, et al. Promotion or suppression of experimental metastasis of B16 melanoma cells after oral administration of lapachol. Toxicol Appl Pharmacol. 2008 Jun 1;229(2):232-8. [Content Brief]

[3]. Iasmin Aparecida Cunha Araújo, et al. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis. Exp Parasitol. 2019 Apr:199:67-73. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.1276 mL	20.6381 mL	41.2763 mL	103.1907 mL
	5 mM	0.8255 mL	4.1276 mL	8.2553 mL	20.6381 mL
	10 mM	0.4128 mL	2.0638 mL	4.1276 mL	10.3191 mL
	15 mM	0.2752 mL	1.3759 mL	2.7518 mL	6.8794 mL
	20 mM	0.2064 mL	1.0319 mL	2.0638 mL	5.1595 mL
	25 mM	0.1651 mL	0.8255 mL	1.6511 mL	4.1276 mL
	30 mM	0.1376 mL	0.6879 mL	1.3759 mL	3.4397 mL
	40 mM	0.1032 mL	0.5160 mL	1.0319 mL	2.5798 mL
	50 mM	0.0826 mL	0.4128 mL	0.8255 mL	2.0638 mL
	60 mM	0.0688 mL	0.3440 mL	0.6879 mL	1.7198 mL
	80 mM	0.0516 mL	0.2580 mL	0.5160 mL	1.2899 mL
	100 mM	0.0413 mL	0.2064 mL	0.4128 mL	1.0319 mL

Keywords

Lapachol

3 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Lapachol

Ferroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Antiparasitic Compound library

Mitochondria-Targeted Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

Natural Product Library Plus

Bioactive Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Lipid Metabolite Compound Library

Mongolian Medicine Compound Library

Quinones Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Publications Citing Use of MedChemExpress (MCE) Lapachol

Ver todos los productos específicos de isoformas DNA/RNA Synthesis

Ver todos los productos específicos de isoformas Parasite

Actividad biológica

Chemical Information

Publications (3)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Lapachol Related Classifications

HY-N6961 Related Classifications